Month: August 2022

ALX Oncology Announces First Patient Dosed in Phase 2 Investigator-Sponsored Trial of Evorpacept in Combination with Cetuximab and Pembrolizumab in Patients with Advanced Colorectal Cancer

08/17/2022

Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif., Aug. 11, 2022 (GLOBE NEWSWIRE) — ALX Oncology Holdings Inc., (“ALX Oncology”) (Nasdaq: ALXO), a clinical-stage immuno-oncology company developing therapies that block the CD47 checkpoint pathway, today announced the initiation of a Phase 2 investigator-sponsored study of evorpacept, a next generation CD47 blocker, in combination with…

Read More

Homology Medicines Announces Optimized, In Vivo Gene Therapy Candidate for the Treatment of Metachromatic Leukodystrophy

08/16/2022

– Candidate Showed Ability to Target Central Nervous System and Peripheral OrgansFollowing a Single I.V. Administration in MLD Model, a Key Differentiator from AvailableTreatments and Product Candidates –        – Data Demonstrated Biodistribution to Brain Regions and Multiple Cell Types –        – Optimizations Included Significant Improvements in Expression, Productivity and Packaging – – Homology Seeks Partner…

Read More

Agios Announces Publication of Phase 2 Data in The Lancet Demonstrating Safety and Efficacy of PYRUKYND® (mitapivat) in Non-transfusion-dependent α- and β-Thalassemia

08/16/2022

– In Adults with Non-transfusion-dependent α- or β-Thalassemia, PYRUKYND® Induced ≥1.0 g/dL Hemoglobin Increase from Baseline in 16 of 20 (80%) Patients Between Weeks 4-12 – – PYRUKYND® Safety Profile Consistent with Label for FDA-approved Indication in Pyruvate Kinase Deficiency – – Actively Enrolling Phase 3 ENERGIZE and ENERGIZE-T Studies Evaluating PYRUKYND® in Adults with Non-transfusion-dependent and Transfusion-dependent α-…

Read More

Regen BioPharma, Inc. Develops Novel Dedifferentiation Approach for Increasing Efficacy of CAR-T Cells to Treat Solid Tumor

08/16/2022

Company Creates “Younger T Cells” for Fighting Cancer Using its NR2F6 Technology Excerpt from the Press Release: SAN DIEGO, Aug. 11, 2022 /PRNewswire/ — Regen BioPharma, Inc. (OTC PINK: RGBP) (OTC PINK: RGBPP) announced today the filing  with the United States Patent and Trademark Office  of a provisional US patent application covering the Company’s novel approach for…

Read More

Satsuma Pharmaceuticals Announces Completion of Enrollment in SUMMIT Pivotal Phase 3 Efficacy Trial of STS101 for the Acute Treatment of Migraine

08/15/2022

– More than 1,400 subjects randomized –– Satsuma expects to announce topline SUMMIT trial results in Q4 2022 – Excerpt from the Press Release: SOUTH SAN FRANCISCO, Calif., Aug. 02, 2022 (GLOBE NEWSWIRE) — Satsuma Pharmaceuticals, Inc. (Nasdaq: STSA), a clinical-stage biopharmaceutical company developing STS101 (dihydroergotamine (DHE) nasal powder), a novel investigational therapeutic product candidate for the…

Read More

Meet with Christopher Kata during “SCDM 2022” September 11th to 13th!

08/15/2022

Christopher Kata and the TrialStat team are exhibiting at this years SCDM meeting on September 13th through the 16th in booth #400. If you’re attending be sure to to reach out to Christopher to schedule a one on meeting or just drop by booth #400 at your convenience! Drop by for a chance to win…

Read More

Orca Bio Announces the Precision-T Phase 3 Study is Open and Enrolling Patients at Transplant Centers Across the U.S.

08/15/2022

– The pivotal Precision-T Study is evaluating the safety and efficacy of Orca Bio’s investigational Orca-T compared to standard of care allogeneic hematopoietic stem cell transplant – – Precision-T is expected to enroll approximately 174 patients across more than 20 clinical trial sites – Excerpt from the Press Release: MENLO PARK, Calif.–(BUSINESS WIRE)–Orca Bio, a late-stage…

Read More

InterVenn Biosciences Announces Start of Enrollment in Colonoscopy Study

08/15/2022

Excerpt from the Press Release: SAN FRANCISCO–(BUSINESS WIRE)–InterVenn® Biosciences, a clinical technology company leveraging glycoproteomics to transform the future of healthcare, today announced the start of enrollment in its prospective cohort study for early detection of colorectal cancer and adenomas. This confirmatory Noninvasive Identification of Colorectal Cancer and Adenomas in Early Stages– better known as…

Read More

Avalo Therapeutics Announces First Patient Dosed in the AVTX-803 Pivotal Trial (LADDER) for the Treatment of Leukocyte Adhesion Deficiency Type II (LAD II)

08/12/2022

Topline Pivotal trial results expected 1H2023 Excerpt from the Press Release: WAYNE, Pa. and ROCKVILLE, Md., Aug. 02, 2022 (GLOBE NEWSWIRE) — Avalo Therapeutics, Inc. (Nasdaq: AVTX), announced the first patient has been dosed in the pivotal LADDER trial (A Phase 3, Randomized, Double-blind, Two-period, Crossover, Withdrawal Study to Assess the Efficacy and Safety of…

Read More

NeuroSense Joins EverythingALS Open Innovation Consortium; Set to Enroll US and EU Patients in Phase IIb Study

08/12/2022

– NeuroSense’s support will aid EverythingALS with ground-breaking patient research in a joint effort to develop treatments – NeuroSense’s CEO to present at EverythingALS’s Expert Talk Series on August 3, 2022; To listen to Mr. Ben-Noon’s Excerpt from the Press Release: LOS ALTOS, Calif. and CAMBRIDGE, Mass., Aug. 2, 2022 /PRNewswire/ — EverythingALS, a patient-focused…

Read More